ADC Therapeutics (ADCT) Amortization of Deferred Charges (2023 - 2026)

ADC Therapeutics (ADCT) has reported Amortization of Deferred Charges for 4 consecutive years, with $225000.0 the latest figure, recorded in Q1 2026.

• Quarterly Amortization of Deferred Charges fell 50.98% year-over-year to $225000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 0.7% YoY) and the FY2025 annual result came in at $1.8 million, down 6.28% from the prior year.
• Amortization of Deferred Charges slipped to $225000.0 in Q1 2026 per ADCT's latest filing, from $246000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for ADCT reached as high as $733000.0 in Q3 2025 and fell as low as $225000.0 in Q1 2026.
• A 4-year average of $485615.4 and a median of $512000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2025 — Amortization of Deferred Charges jumped 47.73% — and 2026, when it tumbled 50.98%.
• Year by year, Amortization of Deferred Charges stood at $512000.0 in 2023, then decreased by 11.72% to $452000.0 in 2024, then slumped by 45.58% to $246000.0 in 2025, then dropped by 8.54% to $225000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $225000.0, $246000.0, and $733000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.